Clinical Trial Update: Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4) [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating elbasvir/grazoprevir in Brazilian participants with chronic HCV genotype 1 and advanced fibrosis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir (elbasvir/grazoprevir)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 4 | Status: WITHDRAWN